Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD

Bone Marrow Transplantation, Published online: 05 January 2024; doi:10.1038/s41409-023-02181-3Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD

https://www.nature.com/articles/s41409-023-02181-3

Source: Bone Marrow Transplantation - January 5, 2024 Category: Hematology Authors: Zahra Hudda Amanda Flannery Ashley Teusink-Cross Stella M. Davies Pooja Khandelwal Source Type: research

More News: Bone Marrow Transplant | Hematology | Skin | Transplants